ORAGENICS

Oragenics are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets. Within oral health we are commercializing our patented probiotic blend, ProBiora3® specifically formulated for oral health both under our branded Evora line and in private label configurations. Currently we have sales or contracts to sell these products in over 15 countries around the world. Our recent partnership with Intrexon in the field of Lantibiotics... , a largely overlooked class of extremely potent gram-positive antibiotics, will help us to develop our pharmaceutical product candidate, MU1140-S™ and additional antibiotics from the Lantibiotic class for therapeutic use. The focus on the probiotic area will be to grow sales through a variety of channels including internet sales and the professional channel (dentists and hygienists) as well as through private label and bulk sales of our patented ProBiora3 blend. We intend to look for opportunities to expand our health claims for these products through a range of clinical studies. We are also looking at novel and convenient new delivery systems for our probiotics, which we plan to commercialize in the near future. In 2011 we received the Frost and Sullivan Award for excellence in probiotics. This was a competitive award that placed us as a leader in the probiotic space.
ORAGENICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Tampa, Florida, United States
Country:
United States
Website Url:
http://www.oragenics.com
Total Employee:
11+
Status:
Active
Contact:
(813)286-7900
Email Addresses:
[email protected]
Total Funding:
98.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2006-11-20 | iviGene | iviGene acquired by Oragenics | N/A |
Official Site Inspections
http://www.oragenics.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.83 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149

More informations about "Oragenics"
About :: Oragenics, Inc. (OGEN)
Investor Relations :: Oragenics, Inc. (OGEN)
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an …See details»
Oragenics - Crunchbase Company Profile & Funding
Oragenics is a development-stage company that primarily engages in fighting infectious diseases, including coronaviruses and multidrug-resistant …See details»
Profile :: Oragenics, Inc. (OGEN)
Oragenics, Inc. is a biotechnology company specializing in nasal drug delivery for neurological and rare diseases. The company’s lead program, ONP-002, is an intranasal neurosteroid in …See details»
Management Team :: Oragenics, Inc. (OGEN)
Currently serving as head of Business Development at Oragenics, he continues to drive operational excellence and business expansion. Gregory holds a B.S. in Business …See details»
Oragenics, Inc. (OGEN) Company Profile & Facts - Yahoo Finance
See the company profile for Oragenics, Inc. (OGEN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Oragenics, Inc. Provides Shareholder Update on Strategic
Jan 21, 2025 Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including …See details»
Oragenics, Inc. (LON:0A64) Company Profile & Overview - Stock …
Feb 12, 2025 Company profile for Oragenics, Inc. (LON:0A64) with a description, list of executives, contact details and other key facts.See details»
Oragenics - businessabc.net
Mar 7, 2025 ORAGENICS, Inc. (NASDAQ: OGEN) was founded in July 1998 by a group of scientists and medical researchers determined to develop innovative medicines to address the …See details»
Collaborations :: Oragenics, Inc. (OGEN)
The NRC is Canada’s largest federal research and development organization, partnering with Canadian industries to take research from the lab to the marketplace. In July 2021, Oragenics’ …See details»
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic …
Mar 27, 2025 ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla., March 27, 2025 (GLOBE …See details»
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic …
Mar 27, 2025 Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the …See details»
Board of Directors :: Oragenics, Inc. (OGEN)
Oragenics announced the signing of an asset purchase agreement with Odyssey Health on October 6, 2023. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, …See details»
Oragenics Company Profile - Office Locations, Competitors ... - Craft
Oragenics has 5 employees at their 1 location and $37.65 k in annual revenue in FY 2023. See insights on Oragenics including office locations, competitors, revenue, financials, executives, …See details»
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of …See details»
A Brief History of Oragenics – CANVAS, SWOT, PESTEL & BCG …
Dec 19, 2024 A Brief History of Oragenics Oragenics is a biopharmaceutical company that specializes in developing novel antibiotics for infectious diseases. Founded in 1996, the …See details»
Oragenics Extends Collaboration with the National Research …
Dec 20, 2021 TAMPA, Fla.-- (BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has extended a licensing and collaboration …See details»
Oragenics, Inc. Provides Q1 2025 Shareholder Update on
6 days ago ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) …See details»
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy …
TAMPA, Fla.-- (BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including …See details»
Oragenics Inc Company Profile - Overview - GlobalData
Oragenics Inc (Oragenics) is a biotechnology company. It specializes in researching and developing nasal delivery pharmaceutical medications targeting neurology and infectious …See details»